Details

Autor(en) / Beteiligte

• Wang, Yunhong
• Zhang, Ke
• Suo, Xiaohui
• Meng, Ning
• Gu, Yuanrui
• Qin, Yilang
• Tu, Yanxia
• Zhang, Xiaohui
• Sun, Guofeng
• Ji, Jiaojiao
• Wu, Weichun
• Cai, Yuqi
• Yang, Kai
• Ouyang, Chenxi
• Qi, Junyuan

Titel

B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma

Ist Teil von

• ESC heart failure, 2024, Vol.11 (1), p.574-580

Erscheinungsjahr

2024

Quelle

Wiley Online Library

Beschreibungen/Notizen

• Patients with multiple myeloma (MM) are likely to achieve poor therapeutic response when organs are involved. We produced anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells, which are in a trial for patients with relapsed/refractory MM. One enrolled patient developed severe heart failure, highly suspected as light chain cardiac amyloidosis. He exhibited increased N-terminal pro-brain natriuretic peptide with a peak of 32 299 ng/mL and heart failure with an ejection fraction of 30%. Anti-BCMA CAR-T cells were administered following lymphodepletion. The patient achieved cardiac response within 1 week with a decrease in N-terminal pro-brain natriuretic peptide by 80%, an increase in ejection fraction from 30% to 56%, and a haematological response with negative minimal residual disease at 1 month and a complete response at 1 year. To date, this patient has maintained good health without heart failure or haematological relapse. Herein, we show the efficacy of anti-BCMA CAR-T cells in patients with MM and severe heart failure.